منابع مشابه
Durvalumab: First Global Approval
Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells. The US FDA has granted durvalumab accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progress...
متن کاملTime‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
Polatuzumab vedotin, an antibody-drug conjugate containing monomethyl auristatin E, was associated with an incidence of grade ≥2 peripheral neuropathy (PN) of 55-72% in patients with indolent non-Hodgkin lymphoma in a phase II study, when dosed 1.8-2.4 mg/kg every 3 weeks until progression or for a maximum of 17 cycles. To quantify the correlation of conjugate exposure and treatment duration wi...
متن کاملBrentuximab Vedotin (SGN-35).
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on Hodgkin lymphoma and anaplastic large cell lymphoma. SGN-35 consists of the cAC10 chimerized IgG1 monoclonal antibody SGN30, modified by the addition of a valine-citrulline dipeptide linker to permit attachment of the potent inhibitor of microtubule polymerization monomethylauristatin...
متن کاملBlood Spotlight Brentuximab vedotin
Delivery of cytotoxic agents specifically to malignant cells has always been a goal of cancer therapy. With the development of monoclonal antibodies for clinical use, this goal has become a reality, and antibody-drug conjugates are now part of standard therapy in diseases such as lymphoma and breast cancer. Brentuximab vedotin, which targets CD30, has contributed to the success of antibody-drug...
متن کاملApproval of the first biosimilar antibodies in Europe
In a defining moment for the European Medicines Agency (EMA) and the biopharmaceutical industry, on June 27, 2013 EMA's Committee for Medicinal Products for Human Use adopted a positive opinion for two biosimilar infliximab products (Celltrion's Remsima® and Hospira's Inflectra®), and recommended that they be approved for marketing in the European Union (EU). The European Commission's decision ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drugs
سال: 2019
ISSN: 0012-6667,1179-1950
DOI: 10.1007/s40265-019-01175-0